Resource-Sparing Curative Treatment for Rectal Cancer

NCT01459328 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2011-10-25

No results posted yet for this study

Summary

This is a prospective, multicentre, randomized clinical trial comparing two different neo-adjuvant radiation-based strategies prior to intended surgery for locally advanced adenocarcinoma of the rectum.

This trial may establish the investigational therapy to be superior to, or at least not inferior to conventional treatment.

Conditions

  • Rectal Carcinoma

Interventions

RADIATION

Radiotherapy

Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day * Injected Leucovorin 20 mg/m2/day for 5 days

RADIATION

Radiotherapy

Conventional long course chemo-radiation: * Radiation 50Gy in 25 daily fractions over 5 weeks * Bolus 5 Fluorouracil 350mg/m2/d for 5 days * Injected Leucovorin 20mg in both the first and last (5th) week of radiation * Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks.

Sponsors & Collaborators

  • Centre Anti Cancer Hopital Frantz Fanon

    collaborator UNKNOWN
  • Hospital A.C. Camargo

    collaborator OTHER
  • Credit Valley Hospital

    collaborator OTHER
  • Instituto Nacional de Cancerologia, Columbia

    collaborator OTHER_GOV
  • University Hospital Sestre Milosrdnice

    collaborator OTHER
  • Minesterio de Cienca, Tecnologia y Medio Ambiente

    collaborator UNKNOWN
  • V.N. Cancer Center GKNM Hospital

    collaborator UNKNOWN
  • Tata Memorial Hospital

    collaborator OTHER_GOV
  • Dr Cipto Mangunkusumo General Hospital

    collaborator OTHER
  • National Cancer Center, Bratislava

    collaborator UNKNOWN
  • University of Cape Town

    collaborator OTHER
  • Catholic University of the Sacred Heart

    collaborator OTHER
  • International Atomic Energy Agency

    lead OTHER_GOV

Principal Investigators

  • Eduardo Rosenblatt · International Atomic Energy Agency

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2013-09-30

Countries

  • Algeria
  • Brazil
  • Canada
  • Colombia
  • Croatia
  • Cuba
  • India
  • Indonesia
  • Italy
  • Slovakia
  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01459328 on ClinicalTrials.gov